Bluejay Diagnostics, Inc. (BJDX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bluejay Diagnostics, Inc. on October 23, 2024, regarding a Special Meeting of Stockholders held on the same date. The company is an emerging growth company incorporated in Delaware with its principal executive offices in Acton, MA.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Voting Results
Shareholders voted on a proposal to amend the Company's certificate of incorporation to effect a reverse stock split. As of the record date (September 9, 2024), there were 25,182,946 shares outstanding. A quorum was established with 6,958,210 shares (42.0%) present or represented by proxy.
| Vote Category | Number of Votes |
|---|---|
| For | 5,358,166 |
| Against | 1,487,443 |
| Abstain | 112,601 |
Proposal 1 was approved. Proposal 2 regarding adjournments was not voted upon.
Outlook, Management Commentary, and Risks
While shareholders approved the authority to conduct a reverse stock split, the final decision to proceed, the effective time, and the exact ratio (between 1-for-20 and 1-for-50) remain at the sole discretion of the Board of Directors. The Board is currently considering implementation details, including timing and ratio, without requiring further shareholder action.
Key Facts for Investor Verification
- Shareholders have authorized a reverse stock split with a ratio between 1-for-20 and 1-for-50.
- The Board of Directors retains full discretion on whether to execute the split and determining the specific ratio.
- The filing contains no financial performance data; investors should refer to recent 10-Q or 10-K filings for financial metrics.
- Approximately 27.6% of outstanding shares voted against the proposal.